{"title":"[百日咳免疫球蛋白在小鼠被动保护试验中的作用持续时间(作者译)]。","authors":"S Sabin, M Schwanig, W Schneider","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The prophylactical effect of human anti-Pertussis immunoglobulin was shown in a passive protection test in mice over a time of 9 days, which is more than three times the half live time. In the agglutination test one could find a half life time of 64.7 hours; in the neutralisation test, which is the only valuable for the clinical effect, we could find an average value of half life time of 51.6 hours. We found a nearly parallel decrease in both titers. In the view of our results we discussed former clinical trials and the prospects for a future use of anti-Pertussis immunoglobulins in prophylaxis and therapy; in both fields only those preparations should be used, which are tested for clinical efficiency in a neutralisation test.</p>","PeriodicalId":23929,"journal":{"name":"Zentralblatt fur Bakteriologie. 1. Abt. Originale. A: Medizinische Mikrobiologie, Infektionskrankheiten und Parasitologie","volume":"249 2","pages":"254-60"},"PeriodicalIF":0.0000,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Duration of efficiency of pertussis immunoglobulin in the passive protection tests in mice (author's transl)].\",\"authors\":\"S Sabin, M Schwanig, W Schneider\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The prophylactical effect of human anti-Pertussis immunoglobulin was shown in a passive protection test in mice over a time of 9 days, which is more than three times the half live time. In the agglutination test one could find a half life time of 64.7 hours; in the neutralisation test, which is the only valuable for the clinical effect, we could find an average value of half life time of 51.6 hours. We found a nearly parallel decrease in both titers. In the view of our results we discussed former clinical trials and the prospects for a future use of anti-Pertussis immunoglobulins in prophylaxis and therapy; in both fields only those preparations should be used, which are tested for clinical efficiency in a neutralisation test.</p>\",\"PeriodicalId\":23929,\"journal\":{\"name\":\"Zentralblatt fur Bakteriologie. 1. Abt. Originale. A: Medizinische Mikrobiologie, Infektionskrankheiten und Parasitologie\",\"volume\":\"249 2\",\"pages\":\"254-60\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1981-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Zentralblatt fur Bakteriologie. 1. Abt. Originale. A: Medizinische Mikrobiologie, Infektionskrankheiten und Parasitologie\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zentralblatt fur Bakteriologie. 1. Abt. Originale. A: Medizinische Mikrobiologie, Infektionskrankheiten und Parasitologie","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
[Duration of efficiency of pertussis immunoglobulin in the passive protection tests in mice (author's transl)].
The prophylactical effect of human anti-Pertussis immunoglobulin was shown in a passive protection test in mice over a time of 9 days, which is more than three times the half live time. In the agglutination test one could find a half life time of 64.7 hours; in the neutralisation test, which is the only valuable for the clinical effect, we could find an average value of half life time of 51.6 hours. We found a nearly parallel decrease in both titers. In the view of our results we discussed former clinical trials and the prospects for a future use of anti-Pertussis immunoglobulins in prophylaxis and therapy; in both fields only those preparations should be used, which are tested for clinical efficiency in a neutralisation test.